Seite 18 von 44
Neuester Beitrag: 05.08.20 14:28
|Eröffnet am:||25.07.17 10:02||von: Evidencebase.||Anzahl Beiträge:||2.077|
|Neuester Beitrag:||05.08.20 14:28||von: Hitman2||Leser gesamt:||149.416|
|Seite: < 1 | ... | 15 | 16 | 17 | | 19 | 20 | 21 | ... 44 >|
Catabasis meldet Zahlen für 2018
"Based on the Company’s current operating plan, Catabasis believes it has sufficient cash to fund operations into the fourth quarter of 2020."
1. Corticosteroids to Emerge as the Top-Selling Product in the Global Market for Duchenne Muscular Dystrophy
Compared to the various products, corticosteroids are likely to emerge as the top-selling products during 2017-2026. By 2026 end, corticosteroids are projected to surpass US$ 9,000 million revenue. Various scientific research has found that compared to various products to treat duchenne muscular dystrophy, corticosteroids help in improving muscle strength for up to two to five years, however, long-term benefit of corticosteroids is still not clear.
As of March 7, 2019, there were approximately 31 holders of record of our common stock. This number of holders of record does not include beneficial owners of our common stock whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. http://ir.catabasis.com/node/8546/html#aa9
freut sich 6,2 Mio Warrants auszuzahlen!
As part of our June 2018 equity financing we issued warrants to purchase an aggregate of 4,200,000 shares of common stock at an exercise price of $12.00 per share, and as part of our February 2019 equity financing we issued warrants to purchase an aggregate of 2,000,000 shares of common stock at an exercise price of $6.25 per share. As of March 7, 2019, all of these warrants remained outstanding http://ir.catabasis.com/node/8546/html#aa9